IRVINE, Calif., April 29, 2013 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today that its iSpO2™ pulse oximeter for iPad, iPhone, and iPod touch and EMMA™ Emergency Capnometer earned JEMS Hot Product awards. Only two companies received dual Hot Product award honors at the EMS Today 2013 Conference & Exposition, the industry's leading emergency medical services (EMS) event held recently in Washington, D.C.
A dozen judges reviewed and evaluated products that had recently been introduced into the emergency service industry by the more than 300 exhibitors at the EMS TODAY Conference & Exhibition and rated each of them on originality, functionality, ease of use, and need in the EMS setting. The top 25 products were then selected as the hottest new products shown at EMS TODAY 2013.
"This year just two companies got two products selected in the top 25 – quite an achievement," said AJ Heightman, editor-in-chief of JEMS. "We have had very few double winners in the past."
The EMMA Mainstream Capnometer measures, displays, and monitors respiratory rate and end-tidal carbon dioxide (EtCO2) continuously when connected to a patient's breathing circuit. EMMA's portability allows for use during cardiopulmonary resuscitation (CPR) and intubation in multiple points of care including pre-hospital, rapid response, emergency medicine, operating room, intensive care unit, and long-term acute care. Because EMMA is integrated into the breathing circuit for easy viewing during CPR and endotracheal tube placement, it is highly accessible during transport and/or emergency ventilation scenarios—allowing quick assessment in just a few seconds.
The Masimo iSpO2™ is a consumer pulse oximeter utilizing Masimo SET® technology – the same technology used in leading hospitals worldwide, providing accurate measurements even during the challenging conditions of motion and low perfusion – for use with iPhone, iPad or iPod touch with 30-pin connector to noninvasively measure blood oxygenation, pulse rate and perfusion index. iSpO2 is for short-term sports and aviation use and is not intended for medical use.
"We are honored that our iSpO2 pulse oximeter and EMMA capnometer received two prestigious JEMS Hot Products Awards at EMS Today, the preeminent conference and exhibition for the emergency services industry," said Jon Coleman, Masimo President of Worldwide Sales and Marketing and Clinical Research. "Masimo has always been committed to taking monitoring technologies to new sites and applications, and we're equally committed to launching more award-winning products."
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to the performance of iSpO2 with Masimo SET technology and its ability to provide accurate measurements even during the challenging conditions of motion and low perfusion; risks related to the performance of EMMA and its ability to provide quick assessment in just a few seconds in all cases, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Phone: (949) 297-7434
Email: [email protected]
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.